Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Allergan Plc (AGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 67,751,264
  • Shares Outstanding, K 334,310
  • Annual Sales, $ 14,571 M
  • Annual Income, $ 14,973 M
  • 36-Month Beta 1.18
  • Price/Sales 4.65
  • Price/Cash Flow 6.23
  • Price/Book 0.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.42 +1.60%
on 09/22/17
237.41 -13.80%
on 09/11/17
-19.10 (-8.54%)
since 08/22/17
3-Month
201.42 +1.60%
on 09/22/17
256.80 -20.31%
on 07/25/17
-42.46 (-17.18%)
since 06/22/17
52-Week
184.50 +10.92%
on 11/23/16
256.80 -20.31%
on 07/25/17
-38.78 (-15.93%)
since 09/22/16

Most Recent Stories

More News
Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia

Allergan plc (NYSE: AGN) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar...

AGN : 204.65 (+0.98%)
New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial

Allergan plc (NYSE:AGN) today announced top-line results from new data for the CENTAUR Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver...

AGN : 204.65 (+0.98%)
How is the Age-Related Macular Degeneration Space Faring Now?

The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.

AGN : 204.65 (+0.98%)
OPHT : 2.69 (unch)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
REGN : 432.72 (-0.17%)
Prescriber's Choice and Sincerus FL Release a Statement Regarding Allergan Lawsuit

Prescriber's Choice Inc. and Sincerus FL, LLC, two companies formed with the goal of providing physicians and patients access to high quality, safe, and affordable medications, responded to a press release...

AGN : 204.65 (+0.98%)
States expand investigation of opioid makers, distributors

Attorneys general from most states are broadening their investigation into the opioid industry as a nationwide overdose crisis continues to claim thousands of lives.

MCK : 154.01 (+0.94%)
AGN : 204.65 (+0.98%)
CAH : 66.66 (-0.16%)
Should Value Investors Consider Allergan plc (AGN) Stock Now?

Is Allergan (AGN) a great pick from the value investor's perspective right now? Read on to know more.

AGN : 204.65 (+0.98%)
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval

The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.

JNJ : 131.39 (-0.27%)
AGN : 204.65 (+0.98%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

ACHN : 4.11 (+0.24%)
LLY : 83.91 (+0.70%)
AGN : 204.65 (+0.98%)
TEVA : 17.19 (+0.23%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
Biosimilar 2017 Progress Report: Stocks in Focus

The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.

MYL : 31.30 (+0.19%)
MRK : 65.13 (-0.72%)
AGN : 204.65 (+0.98%)
NVS : 86.16 (+1.44%)
MNTA : 17.15 (+2.08%)
AMGN : 185.76 (-0.47%)
BIIB : 318.46 (+1.09%)
FDA Approves Amgen And Allergan's MVASI(TM) (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI(TM) (bevacizumab-awwb) for all eligible indications of the reference...

AGN : 204.65 (+0.98%)
AMGN : 185.76 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Support & Resistance

2nd Resistance Point 212.94
1st Resistance Point 208.79
Last Price 204.65
1st Support Level 200.96
2nd Support Level 197.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.